Skip to main content

Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration.

Publication ,  Journal Article
Wen, JC; Reina-Torres, E; Sherwood, JM; Challa, P; Liu, KC; Li, G; Chang, JYH; Cousins, SW; Schuman, SG; Mettu, PS; Stamer, WD; Overby, DR ...
Published in: Invest Ophthalmol Vis Sci
March 1, 2017

PURPOSE: We assess the effect of intravitreal anti-VEGF injections on tonographic outflow facility. METHODS: Patients with age-related macular degeneration who had received unilateral intravitreal anti-VEGF injections were recruited into two groups, those with ≤10 and those with ≥20 total anti-VEGF injections. Intraocular pressure and tonographic outflow facility of injected and uninjected fellow eyes were measured and compared between groups. Risk factors for development of reduced outflow facility also were assessed. RESULTS: Outflow facility was 12% lower in the injected eyes of patients who received ≥20 anti-VEGF injections, compared to contralateral uninjected eyes (P = 0.02). In contrast, there was no facility reduction for patients with ≤10 anti-VEGF injections (P = 0.4). In patients with ocular hypertension in the uninjected eye (IOP > 21 mm Hg, n = 5), the outflow facility of injected eyes was on average 46% lower (P = 0.01) than in the uninjected fellow eyes. This was significantly greater than the difference observed in patients with IOP ≤ 21 mm Hg in the uninjected eye (P = 2 × 10-4). In patients with ocular hypertension in the injected eye (n = 6) the differences in facility and IOP between contralateral eyes were significantly greater than in patients with IOP ≤ 21 mm Hg in the injected eye (P = 2 × 10-4 and P = 7 × 10-4, respectively). CONCLUSIONS: Chronic anti-VEGF injections significantly reduce outflow facility in patients with AMD. The greatest facility reduction is observed in patients with baseline ocular hypertension. Ophthalmologists who administer anti-VEGF injections should be aware of these findings and monitor patients closely for changes in IOP or evidence of glaucoma, especially in those with pre-existing ocular hypertension.

Duke Scholars

Published In

Invest Ophthalmol Vis Sci

DOI

EISSN

1552-5783

Publication Date

March 1, 2017

Volume

58

Issue

3

Start / End Page

1893 / 1898

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Treatment Outcome
  • Tonometry, Ocular
  • Time Factors
  • Ranibizumab
  • Ophthalmology & Optometry
  • Middle Aged
  • Male
  • Intravitreal Injections
  • Intraocular Pressure
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wen, J. C., Reina-Torres, E., Sherwood, J. M., Challa, P., Liu, K. C., Li, G., … Allingham, R. R. (2017). Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 58(3), 1893–1898. https://doi.org/10.1167/iovs.16-20786
Wen, Joanne C., Ester Reina-Torres, Joseph M. Sherwood, Pratap Challa, Katy C. Liu, Guorong Li, Jason Y. H. Chang, et al. “Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration.Invest Ophthalmol Vis Sci 58, no. 3 (March 1, 2017): 1893–98. https://doi.org/10.1167/iovs.16-20786.
Wen JC, Reina-Torres E, Sherwood JM, Challa P, Liu KC, Li G, et al. Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1893–8.
Wen, Joanne C., et al. “Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration.Invest Ophthalmol Vis Sci, vol. 58, no. 3, Mar. 2017, pp. 1893–98. Pubmed, doi:10.1167/iovs.16-20786.
Wen JC, Reina-Torres E, Sherwood JM, Challa P, Liu KC, Li G, Chang JYH, Cousins SW, Schuman SG, Mettu PS, Stamer WD, Overby DR, Allingham RR. Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1893–1898.

Published In

Invest Ophthalmol Vis Sci

DOI

EISSN

1552-5783

Publication Date

March 1, 2017

Volume

58

Issue

3

Start / End Page

1893 / 1898

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Treatment Outcome
  • Tonometry, Ocular
  • Time Factors
  • Ranibizumab
  • Ophthalmology & Optometry
  • Middle Aged
  • Male
  • Intravitreal Injections
  • Intraocular Pressure